Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM‐HF and ATMOSPHERE

Author:

Dewan Pooja1,Ferreira João Pedro2,Butt Jawad H.13,Petrie Mark C.1,Abraham William T.4,Desai Akshay S.5,Dickstein Kenneth6,Køber Lars3,Packer Milton7,Rouleau Jean L.8,Stewart Simon9,Swedberg Karl10,Zile Michael R.11,Solomon Scott D.5,Jhund Pardeep S.1,McMurray John J.V.1

Affiliation:

1. BHF Cardiovascular Research Centre University of Glasgow Glasgow UK

2. Department of Surgery and Physiology, Cardiovascular Research and Development Unit, Faculty of Medicine University of Porto Porto Portugal

3. Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

4. Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute Ohio State University Columbus OH USA

5. Cardiovascular Division Brigham and Women's Hospital Boston MA USA

6. Stavanger University Hospital, Stavanger, and the Institute of Internal Medicine University of Bergen Bergen Norway

7. Baylor Heart and Vascular Institute Baylor University Medical Center Dallas TX USA

8. Institut de Cardiologie de Montréal Université de Montréal Montreal QC Canada

9. Institute for Health Research University of Notre Dame Fremantle WA Australia

10. Department of Molecular and Clinical Medicine University of Gothenburg Gothenburg Sweden

11. Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center Charleston SC USA

Abstract

ABSTRACTAimsMultimorbidity, the coexistence of two or more chronic conditions, is synonymous with heart failure (HF). How risk related to comorbidities compares at individual and population levels is unknown. The aim of this study is to examine the risk related to comorbidities, alone and in combination, both at individual and population levels.Methods and resultsUsing two clinical trials in HF – the Prospective comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin‐Converting Enzyme Inhibitor) to Determine Impact on Global Mortality and morbidity in HF trial (PARADIGM‐HF) and the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure trials (ATMOSPHERE) – we identified the 10 most common comorbidities and examined 45 possible pairs. We calculated population attributable fractions (PAF) for all‐cause death and relative excess risk due to interaction with Cox proportional hazard models. Of 15 066 patients in the study, 14 133 (93.7%) had at least one and 11 867 (78.8%) had at least two of the 10 most prevalent comorbidities. The greatest individual risk among pairs was associated with peripheral artery disease (PAD) in combination with stroke (hazard ratio [HR] 1.73; 95% confidence interval [CI] 1.28–2.33) and anaemia (HR 1.71; 95% CI 1.39–2.11). The combination of chronic kidney disease (CKD) and hypertension had the highest PAF (5.65%; 95% CI 3.66–7.61). Two pairs demonstrated significant synergistic interaction (atrial fibrillation with CKD and coronary artery disease, respectively) and one an antagonistic interaction (anaemia and obesity).ConclusionsIn HF, the impact of multimorbidity differed at the individual patient and population level, depending on the prevalence of and the risk related to each comorbidity, and the interaction between individual comorbidities. Patients with coexistent PAD and stroke were at greatest individual risk whereas, from a population perspective, coexistent CKD and hypertension mattered most.

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3